Display options
Cite
Gangneux JP, El Cheikh J, Herbrecht R, et al. Systemic Antifungal Prophylaxis in Patients Hospitalized in Hematology Units in France: The AFHEM Cross-Sectional Observational Study. Infect Dis Ther. 2018;7(3):309-325doi: 10.1007/s40121-018-0203-4.
Gangneux, J. P., El Cheikh, J., Herbrecht, R., Yakoub-Agha, I., Quiniou, J. B., Caillot, D., & Michallet, M. (2018). Systemic Antifungal Prophylaxis in Patients Hospitalized in Hematology Units in France: The AFHEM Cross-Sectional Observational Study. Infectious diseases and therapy, 7(3), 309-325. https://doi.org/10.1007/s40121-018-0203-4
Gangneux, Jean-Pierre, et al. "Systemic Antifungal Prophylaxis in Patients Hospitalized in Hematology Units in France: The AFHEM Cross-Sectional Observational Study." Infectious diseases and therapy vol. 7,3 (2018): 309-325. doi: https://doi.org/10.1007/s40121-018-0203-4
Gangneux JP, El Cheikh J, Herbrecht R, Yakoub-Agha I, Quiniou JB, Caillot D, Michallet M. Systemic Antifungal Prophylaxis in Patients Hospitalized in Hematology Units in France: The AFHEM Cross-Sectional Observational Study. Infect Dis Ther. 2018 Sep;7(3):309-325. doi: 10.1007/s40121-018-0203-4. Epub 2018 Jun 09. PMID: 29948621; PMCID: PMC6098753.
Copy Download .nbib Format: NLM
Share it on

Infect Dis Ther. 2018 Sep;7(3):309-325. doi: 10.1007/s40121-018-0203-4. Epub 2018 Jun 09.

Systemic Antifungal Prophylaxis in Patients Hospitalized in Hematology Units in France: The AFHEM Cross-Sectional Observational Study.

Infectious diseases and therapy

Jean-Pierre Gangneux, Jean El Cheikh, Raoul Herbrecht, Ibrahim Yakoub-Agha, Jean-Baptiste Quiniou, Denis Caillot, Mauricette Michallet

Affiliations

  1. Department of Parasitology and Myology, Hospital Pontchaillou, Rennes, France. [email protected].
  2. Department of Transplantation and Cellular Therapy, Paoli Calmettes Institute, Marseille, France.
  3. Department of Oncology and Hematology, Strasbourg, France.
  4. LIRIC INSERM U995, Affiliated University Hospital, Lille 2 University, Lille, France.
  5. Department of Medical Affairs, Astellas Pharma France, Levallois-Perret, France.
  6. Department of Clinical Hematology, Affiliated University Hospital, Dijon, France.
  7. Department of Clinical Hematology, Hospital Lyon-Sud, Pierre-Bénite, France.

PMID: 29948621 PMCID: PMC6098753 DOI: 10.1007/s40121-018-0203-4

Abstract

INTRODUCTION: The frequency of invasive fungal diseases (IFDs) has increased in recent years. Within a context where both treatments and guidelines are fast evolving, we aim to shed new light on IFD management in hematologic departments in France.

METHODS: A multicenter cross-sectional observational study was prospectively conducted in 24 French centers in September and October 2013.

RESULTS: Four hundred ninety-four hospitalized children and adult patients suffering from hematologic malignancy were enrolled: 147 (30%) were allogeneic hematopoietic stem cell transplant (HSCT) recipients, 131 (27%) were patients with acute myeloblastic leukemia or myelodysplastic syndrome (MDS), 71 (14%) were patients with acute lymphoblastic leukemia who did not undergo allogeneic HSCT, and the 145 (29%) remaining patients did not belong to the three above groups. Two hundred forty-six patients (50%) received antifungal treatment, which was prophylactic in 187 (76%) treated patients. These rates were similar across all groups (63-80%). Patients received prophylaxis with an azole (79%), intravenous amphotericin B formulation (10%), echinocandin (9%), or two combination drugs (2%).

CONCLUSION: Results indicate that prophylaxis is the leading antifungal strategy in French hematology units, regardless of the disease condition, representing 76% of prescriptions for antifungal therapy.

FUNDING: Astellas Pharma France.

Keywords: Antifungal prophylaxis; Hematology; Invasive fungal disease; Systemic antifungal treatment

References

  1. N Engl J Med. 2007 Jan 25;356(4):335-47 - PubMed
  2. Clin Infect Dis. 2009 Apr 15;48(8):1042-51 - PubMed
  3. Eur J Haematol. 2011 Oct;87(4):289-301 - PubMed
  4. Bone Marrow Transplant. 2011 May;46(5):709-18 - PubMed
  5. Blood Rev. 2017 Mar;31(2):17-29 - PubMed
  6. J Antimicrob Chemother. 2012 Nov;67(11):2731-8 - PubMed
  7. J Antimicrob Chemother. 2013 Nov;68 Suppl 3:iii17-iii24 - PubMed
  8. Intern Med J. 2014 Dec;44(12b):1283-97 - PubMed
  9. Int J Antimicrob Agents. 2008 Nov;32 Suppl 2:S143-7 - PubMed
  10. J Mycol Med. 2016 Dec;26(4):385-390 - PubMed
  11. Mycoses. 2015 Jun;58 Suppl 2:14-25 - PubMed
  12. Clin Microbiol Infect. 2012 Dec;18 Suppl 7:53-67 - PubMed
  13. Mycoses. 2009 May;52(3):197-205 - PubMed
  14. Haematologica. 2009 Jan;94(1):113-22 - PubMed
  15. J Antimicrob Chemother. 2011 Jan;66 Suppl 1:i5-14 - PubMed
  16. N Engl J Med. 2002 Aug 8;347(6):408-15 - PubMed
  17. Rev Esp Quimioter. 2011 Dec;24(4):263-70 - PubMed
  18. Antimicrob Agents Chemother. 2011 Nov;55(11):5358-61 - PubMed
  19. Ann Hematol. 2009 Feb;88(2):97-110 - PubMed
  20. Haematologica. 2011 Feb;96(2):e9-10; author reply e11 - PubMed
  21. Clin Infect Dis. 2009 Mar 1;48(5):503-35 - PubMed

Publication Types